A Metformin Pharmacogenetic Study of Patients with Type 2 Diabetes Mellitus and SLC22A1 Gene Mutation

Background: The purpose of this study was to determine the profiles patients with type 2 diabetes (T2DM) and an SLC22A1 gene mutation in order evaluate effect metformin pharmacogenetics.
 Methods: To assess pharmacogenetics, a T2DM receiving investigated. Blood samples were taken from 50 diabetics Minangkabau ethnicity who met inclusion criteria, SNP genotyping blood glucose levels determined. DNA is extracted purified using DNAzol® Genomic Kits (Thermofischer Scientific) reagents. Chi-square test Independent sample T used analyze data. A statistically significant association defined as p-value < 0.05. Finally, GraphPad Prism 7.00 program gather data.
 Results: adjusted odds ratio for inadequate fasting 1.48 (95% CI 1.18-1.95) study, while diet discipline 1.23 1.18-1.95). low physical activity 1.18. 1.05-1.81). According sequencing data, proportion mutants high at exon rs683369 (G> C), percentage wildtype heterozygous same introns rs4646272 (T> G).
 Conclusion: Obesity, discipline, all found increase likelihood insufficient patients. Exon C) has mutants, but G) have mutants.